Top

Published in:

01-03-2022 | Guillain-Barré Syndrome | Original Article

Ten years evaluation of epidemiology- and mortality-related factors in adults and children with Guillain-Barré syndrome in the north of Iran

Authors: Mozaffar Hosseininezhad, Seyed Sepehr Khatami, Sajjad Saadat, Mona Asghari, Hoora Ghovvati Choshal, Alireza Hooshmand Marvasti, Zahra Gholipour Soleimani

Published in: Neurological Sciences | Issue 3/2022

Abstract

Background

Guillain-Barré syndrome (GBS) is the main cause of acute and subacute flaccid paralysis in western nations since the eradication of poliomyelitis.

Objective

The aim of this study is to investigate epidemiology and mortality characteristics of GBS in the north of Iran.

Material and methods

In this study, the hospital information system (HIS) was used to access each patient’s information. The final 174 cases were examined in terms of age, sex, place of residence, the year of referral, the month of referral, the season of referral, client city, accompanying background disease, and the type of GBS.

Results

The mean incidence rate in Guilan province was about 0.69 in 100,000 persons, and the case fatality rate was 10.34%. The most reported type of GBS was AIDP (33.90%), and the most common symptom was upper and lower limbs paresis in 65 cases (37%). Respiratory distress (P = < 0.001), complications during hospitalization (P = 0.0001), and ICU requirement (P = 0.001) were significantly higher in dead patients.

Conclusion

In this study, the incidence of GBS was higher in men than women and the highest number of cases was in the age group of 60 to 75 years. The significant point was the high-case fatality rate in Guilan province compared to the previous studies. The complications during hospitalization such as respiratory distress, ICU requirement, and underlying disease had a significant relation with the fatality of GBS.

Available only for authorised users

Pithadia AB, Kakadia N (2010) Guillain-Barré syndrome (GBS). Pharmacol Rep 62(2):220–232CrossRef

Sipilä JO et al (2017) Epidemiology of Guillain-Barré syndrome in Finland 2004–2014. J Peripher Nerv Syst 22(4):440–445CrossRef

El-Beleidy AS et al (2013) Antiganglioside antibodies determine the clinical severity and predict response to therapy in Egyptian children with Guillain-Barré Syndrome. Pediatr Pol 88(3):224–229CrossRef

Jacobs BC et al (2017) International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. J Peripher Nerv Syst 22(2):68–76CrossRef

Benedetti MD et al (2015) A multicentric prospective incidence study of Guillain-Barré syndrome in Italy. the ITANG study. Neuroepidemiology 45(2):90–99CrossRef

Momen AA, Shakurnia A (2017) The epidemiology of guillain-barré syndrome in children under 15 years old in Southwest Iran. Biomed Hub 2(3):1–8CrossRef

Kwong JC et al (2013) Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis 13(9):769–776CrossRef

Wachira VK, Peixoto HM, de Oliveira MRF (2019) Systematic review of factors associated with the development of Guillain-Barré syndrome 2007–2017: what has changed? Tropical Med Int Health 24(2):132–142CrossRef

Ogawara K et al (2000) Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 48(4):624–631CrossRef

10.

Kobori S et al (2017) Coexisting infectious diseases on admission as a risk factor for mechanical ventilation in patients with Guillain-Barré syndrome. J Epidemiol 27(7):311–316CrossRef

11.

Parra B et al (2016) Guillain-Barré syndrome associated with Zika virus infection in Colombia. N Engl J Med 375(16):1513–1523CrossRef

12.

Grave C et al (2020) Seasonal influenza vaccine and Guillain-Barré syndrome: a self-controlled case series study. Neurology 94(20):e2168–e2179CrossRef

13.

Racca F et al (2020) Practical approach to respiratory emergencies in neurological diseases. Neurol Sci 41(3):497–508CrossRef

14.

Wijdicks EF, Klein CJ (2017) Guillain-barré syndrome. In Mayo clinic proceedings, vol 92, No. 3. Elsevier, pp 467–479

15.

Hughes RA, Swan AV, van Doorn PA (2014) Intravenous immunoglobulin for Guillain-Barré syndrome. Cochr Database Syst Rev 2014(9):CD002063. https://doi.org/10.1002/14651858.CD002063.pub6

16.

Li C et al (2020) The effects of IVIg therapy on serum levels of neuropeptide Y and cytokines in Guillain-Barré syndrome. Neurol Sci 41(2):295–303CrossRef

17.

Arami MA, Yazdchi M, Khandaghi R (2006) Epidemiology and characteristics of Guillain-Barre syndrome in the northwest of Iran. Ann Saudi Med 26(1):22–27CrossRef

18.

Yadegari S, Kazemi N, Nafissi S (2014) Clinical and electrophysiological features of Guillain-Barré syndrome in Iran. J Clin Neurosci 21(9):1554–1557CrossRef

19.

Alshekhlee A et al (2008) Guillain-Barré syndrome: incidence and mortality rates in US hospitals. Neurology 70(18):1608–1613CrossRef

20.

Yakoob MY et al (2005) Characteristics of patients with Guillain Barre Syndrome at a tertiary care centre in Pakistan, 1995–2003. J Pak Med Assoc 55(11):493PubMed

21.

Said SD (2009) Clinical experience with Gullain Barre syndrome over a 6-year period in one hospital in the Middle East. Jordan Med J 43(4):280–285

22.

Radhakrishnan K, El-Mangoush M, Gerryo S (1987) Descriptive epidemiology of selected neuromuscular disorders in Benghazi, Libya. Acta Neurol Scand 75(2):95–100CrossRef

23.

Bölükbaşi F et al (2019) Guillain-barré syndrome and its variants: Clinical course and prognostic factors. Arch Neuropsychiatry 56(1):71

24.

Benamer HT, Bredan A (2014) Guillain-Barré syndrome in Arab countries: a systematic review. J Neurol Sci 343(1–2):221–223CrossRef

25.

Granieri E et al (2019) Incidence study of Guillain-Barré syndrome in the province of Ferrara, Northern Italy, between 2003 and 2017. A 40-year follow-up. Neurol Sci 40(3):603–609CrossRef

26.

Al-Hakem H et al (2019) Guillain-Barré syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity. J Neurol 266(2):440–449CrossRef

27.

van Doorn PA (2013) Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS). La Presse Médicale 42(6 Part 2):e193–e201CrossRef

28.

Pritchard J (2010) Guillain-Barré syndrome. Clin Med (Lond) 10(4):399–401CrossRef

29.

Incecik F, Hergüner MO, Altunbasak S (2011) Guillain-Barré syndrome in children. Neurol Sci 32(3):381–385CrossRef

30.

Lin J-J et al (2012) Clinical variants of Guillain-Barré syndrome in children. Pediatr Neurol 47(2):91–96CrossRef

31.

Koul R et al (2008) Clinical characteristics of childhood guillain-barré syndrome. Oman Med J 23(3):158PubMedPubMedCentral

32.

Wang Y et al (2016) Complications of Guillain-Barré syndrome. Expert Rev Clin Immunol 12(4):439–448CrossRef

33.

Kim J-E et al (2017) Neurological complications during treatment of Middle East respiratory syndrome. J Clin Neurol (Seoul, Korea) 13(3):227CrossRef

34.

Rahimi K (2020) Guillain-Barre syndrome during COVID-19 pandemic: an overview of the reports. Neurol Sci 41(11):3149–3156CrossRef

35.

Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M (2021) Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol 268(4):1133–1170

36.

Alberti P, Beretta S, Piatti M, Karantzoulis A, Piatti ML, Santoro P, Ferrarese C (2020) Guillain-Barré syndrome related to COVID-19 infection. Neurol-Neuroimmunol Neuroinflam 7(4)

37.

Caress JB et al (2020) COVID-19–associated Guillain-Barré syndrome: the early pandemic experience. Muscle Nerve 62(4):485–491CrossRef

38.

Sedaghat Z, Karimi N (2020) Guillain Barre syndrome associated with COVID-19 infection: a case report. J Clin Neurosci 76:233–235CrossRef

39.

Uncini A, Vallat J-M, Jacobs BC (2020) Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry 91(10):1105–1110CrossRef

40.

Haber P et al (2004) Guillain-Barré syndrome following influenza vaccination. JAMA 292(20):2478–2481CrossRef

41.

Polack FP et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383(27):2603–2615CrossRef

42.

Oliver SE (2020) The advisory committee on immunization practices’ interim recommendation for use of moderna COVID-19 vaccine—United States, December 2020. MMWR. Morbid Mortal Week Rep 69

Title: Ten years evaluation of epidemiology- and mortality-related factors in adults and children with Guillain-Barré syndrome in the north of Iran
Authors: Mozaffar Hosseininezhad
Seyed Sepehr Khatami
Sajjad Saadat
Mona Asghari
Hoora Ghovvati Choshal
Alireza Hooshmand Marvasti
Zahra Gholipour Soleimani
Publication date: 01-03-2022
Publisher: Springer International Publishing
Keyword: Guillain-Barré Syndrome
Published in: Neurological Sciences / Issue 3/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-021-05562-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ten years evaluation of epidemiology- and mortality-related factors in adults and children with Guillain-Barré syndrome in the north of Iran

Abstract

Background

Objective

Material and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Material and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2022

Management of chronic migraine with medication overuse by web-based behavioral program during the COVID-19 emergency: results at 12 months

The clinical and paraclinical correlates of employment status in multiple sclerosis

Effect of ketogenic diet for drug-resistant epilepsy on immunological cells

HSV encephalitis associated with off-label rituximab treatment of multiple sclerosis

The cognitive impact of guard shifts in physicians: a before-after study

Correction to: Psychological well‑being in people with multiple sclerosis: a descriptive review of the effects obtained with mindfulness interventions